LIVE
BSX
Boston Scientific Corporation · Healthcare
$45.29
-20.28% this month
VERSUS
⟷
COMPARE
MDT
Medtronic plc · Healthcare
$79.34
+0.97% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BSX
1
MDT
4
Comparison scoreboard
MDT LEADS 4/5AI Score
BSX 40.2
MDT ✓40.3
1Y Return
BSX -55.48%
MDT ✓-7.93%
Fwd P/E
BSX 12.59
MDT ✓12.52
Target Up.
BSX ✓+64.36%
MDT +22.19%
Op. Margin
BSX 20.60%
MDT ✓21.30%
Metrics last refreshed: 6/20/2026
Quick take
BSX vs MDT Stock Comparison: AI Score, Valuation, Performance and Upside
Boston Scientific and Medtronic are both large-cap medtech leaders in cardiovascular and other device categories, but with very different recent performance. BSX has consistently grown faster with FARAPULSE, Watchman, and a strong M&A pipeline. Medtronic has the larger revenue base but has underperformed on organic growth while pursuing Hugo robotic surgery and Ardian as turnaround catalysts. Both pay dividends, but BSX's growth is the primary differentiation.
BSX vs MDT is the high-growth interventional cardiology innovator (Boston Scientific) versus the large-scale diversified medtech turnaround story (Medtronic) — BSX's FARAPULSE momentum and M&A track record contrast with Medtronic's scale and dividend reliability but lagging organic growth.
Live analysis · updated 6/20/2026
MDT holds the edge across 4 of 5 key metrics in this comparison. MDT leads on both 1-year return (-7.93%) and forward P/E (12.52x vs 12.59x for BSX), a relatively favorable combination of momentum and valuation. On fundamentals, BSX is growing revenue faster (11.60%), while MDT maintains the higher operating margin (21.30%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for BSX (+64.36%) than for MDT (+22.19%).
Normalized 1Y performance
BSX
MDT
Recent returns
BSX
MDT
Analyst price targets & sentiment
BSX
Price target range
analyst mean$77.10
current price$45.29
+64.4% upside to analyst mean
MDT
Price target range
analyst mean$98.00
current price$79.34
+22.2% upside to analyst mean
Who should consider this stock?
BSX may suit investors who:
- →prefer the fastest-growing large-cap medtech company with FARAPULSE PFA as a category-defining atrial fibrillation treatment
- →value Boston Scientific's M&A track record adding innovative capabilities without overpaying relative to synergies realized
- →want medtech exposure with above-market organic revenue growth and strong cardiology procedure volume growth
- →are comfortable with premium valuation (40–50x earnings) requiring sustained above-market execution
MDT may suit investors who:
- →prefer the world's largest medtech with 40+ year consecutive dividend growth as a reliable income investment
- →value Medtronic's global distribution scale and CRM installed base providing resilient revenue across economic conditions
- →want medtech turnaround upside if Hugo robot and Ardian renal denervation succeed in gaining commercial traction
- →are comfortable with organic growth lagging peers and Hugo competing against Intuitive Surgical's da Vinci dominance
Performance & AI score
| Metric | BSX | MDT |
|---|---|---|
| AI score | 40.2 | 40.3 |
| AI rank | #1072 | #1065 |
| Latest close | $45.29 | $79.34 |
| 1M return | -20.28% | +0.97% |
| 6M return | -52.06% | -19.29% |
| 1Y return | -55.48% | -7.93% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BSX | MDT |
|---|---|---|
| 1Y ago | $4.47K (-55.3%) started 2025-06-18 | $9.25K (-7.5%) started 2025-06-18 |
| 5Y ago | $10.39K (+3.9%) started 2021-06-21 | $8.12K (-18.8%) started 2021-06-21 |
| 10Y ago | $19.82K (+98.2%) started 2016-06-20 | $15.14K (+51.4%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BSX | MDT |
|---|---|---|
| Market cap | $69.72B | $102.97B |
| Trailing P/E | 19.63 | 21.50 |
| Forward P/E | 12.59 | 12.52 |
| Price/Sales | N/A | N/A |
| EV/Revenue | 3.86 | 3.38 |
| Analyst target | $77.10 | $98.00 |
| Target upside | +64.36% | +22.19% |
Growth, profitability & risk
| Metric | BSX | MDT |
|---|---|---|
| Revenue growth | 11.60% | 9.90% |
| Earnings growth | 100.00% | 17.10% |
| EPS growth | +100.00% | +17.10% |
| FCF margin | +13.62% | +11.20% |
| Operating margin | 20.60% | 21.30% |
| Profit margin | 17.29% | 13.20% |
| ROIC proxy | 14.66% | 9.93% |
| Return on equity | 14.66% | 9.93% |
| Dividend yield | N/A | 3.59% |
| Beta | 0.56 | 0.60 |
| Debt/equity | 42.25 | 57.06 |
| Current ratio | 1.90 | 2.54 |
| Quick ratio | 0.98 | 1.55 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BSX max drawdown58.43%
MDT max drawdown30.00%
BSX max wkly drop19.50%
MDT max wkly drop7.05%
5Y risk snapshot
BSX max drawdown58.43%
MDT max drawdown45.10%
BSX max wkly drop19.50%
MDT max wkly drop11.81%
10Y risk snapshot
BSX max drawdown58.43%
MDT max drawdown45.10%
BSX max wkly drop19.55%
MDT max wkly drop19.36%
Performance metrics by period
| Period | Metric | BSX | MDT |
|---|---|---|---|
| 1Y | Growth | -55.32% | -7.45% |
| CAGR | -55.37% | -7.46% | |
| Sharpe ratio | -2.26 | -0.47 | |
| Max drawdown | 58.43% | 30.00% | |
| Max daily drop | 17.59% | 3.91% | |
| Max wkly drop | 19.50% | 7.05% | |
| 5Y | Growth | +3.88% | -28.64% |
| CAGR | +0.76% | -6.54% | |
| Sharpe ratio | -0.01 | -0.40 | |
| Max drawdown | 58.43% | 45.10% | |
| Max daily drop | 17.59% | 7.26% | |
| Max wkly drop | 19.50% | 11.81% | |
| 10Y | Growth | +98.21% | +17.72% |
| CAGR | +7.09% | +1.65% | |
| Sharpe ratio | 0.22 | -0.01 | |
| Max drawdown | 58.43% | 45.10% | |
| Max daily drop | 17.59% | 12.82% | |
| Max wkly drop | 19.55% | 19.36% |
Business comparison
| Category | BSX | MDT |
|---|---|---|
| Company | Boston Scientific Corporation | Medtronic plc |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | Boston Scientific is a large-cap medical device company focused on minimally invasive interventional cardiology, electrophysiology, urology, endoscopy, and neuromodulation. Recent growth drivers include FARAPULSE pulsed field ablation (PFA) for atrial fibrillation, Watchman left atrial appendage closure device, and ACURATE neo2 transcatheter aortic valve replacement (TAVR). BSX has a strong track record of organic innovation and accretive acquisitions (Silk Road Medical, Axonics), delivering above-market revenue growth. | Medtronic is the world's largest medical device company by revenue, serving cardiovascular, neuroscience, medical-surgical, and diabetes markets across 150+ countries. Despite its scale, Medtronic has underperformed medtech growth rates due to execution challenges in cardiac rhythm management (CRM), some product launch delays, and a complex organizational structure from decades of acquisitions. The Hugo robotic surgery system and Ardian renal denervation system are key growth bets. |
| Investor focus | Investors track organic revenue growth vs peers, FARAPULSE PFA adoption in the electrophysiology market, Watchman LAAC market share, TAVR launch progress, and the M&A pipeline for capability additions. | Investors track organic revenue growth recovery (Medtronic has lagged peers), Hugo surgical robot adoption, Ardian renal denervation market development, and dividend sustainability from diversified global medtech cash flows. |
BSX strengths
- →FARAPULSE PFA is revolutionizing atrial fibrillation ablation — the technology enables faster, more reproducible procedures attracting rapid physician adoption
- →Consistently above-market organic revenue growth in the high-single-digit percentage range outpaces most large-cap medtech peers
- →Active M&A pipeline acquires innovative smaller medtech companies to augment organic innovation across device categories
MDT strengths
- →World's largest medtech revenue base ($32B+) provides scale for global distribution, regulatory relationships, and manufacturing
- →Dividend payer with 40+ consecutive years of dividend increases — one of the most reliable medtech income investments
- →Hugo surgical robot positions Medtronic in the fast-growing minimally invasive surgery market alongside Intuitive Surgical
Risks to watch — BSX
- →Premium valuation (40–50x earnings) requires sustained above-market revenue growth to justify — any slowdown would compress multiple
- →FARAPULSE manufacturing scale-up must keep pace with rapid physician adoption demand
- →Medtronic and Abbott compete directly in electrophysiology and cardiac rhythm management with their own PFA and next-gen catheter ablation programs
Risks to watch — MDT
- →Organic revenue growth has consistently lagged Boston Scientific and other medtech peers for several years — execution improvement is the primary challenge
- →Hugo robot adoption is still early — Intuitive Surgical's da Vinci has dominant market penetration that Hugo must overcome
- →CRM business faces FARAPULSE and Abbott competition in atrial fibrillation ablation reducing Medtronic's cardiac rhythm procedure share
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →